Forward P/S Multiple: ReShape Lifesciences, Inc. (RSLS)
ReShape Lifesciences (RSLS) relies on the precision final assembly of weight loss systems while maintaining moderate procurement of external components. However, poor scalability and certification costs are keeping margins at zero. The implementation of ESG standards is optimizing production energy costs. This chart of the projected P/S from the GURU.Markets terminal shows that 1.60 forms the current metric value.
Summary analytical data breakdowns for reshapelifesciences.com (RSLS)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital ReShape Lifesciences|RSLS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital ReShape Lifesciences Inc.|RSLS - Company Aggregate Debts|Debt to Book Capitalization Ratio ReShape Lifesciences|RSLS - Company Long-Term Debt|Company Current Liabilities ReShape Lifesciences|Quick Ratio reshapelifesciences.com
- financial results and valuation multiples details:
RSLS - Company Net Income|Expected Profit ReShape Lifesciences|RSLS - Market Cap to Net Income Ratio|Projected Price to Earnings ReShape Lifesciences Inc.|RSLS - PEG Multiple|EV/EBITDA Multiple ReShape Lifesciences|RSLS - Operating income before deduction of amortization|Earnings per share for the last twelve months ReShape Lifesciences|RSLS - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months reshapelifesciences.com|RSLS - Net earnings per share growth this year|Earnings growth forecast for next year ReShape Lifesciences
- sales and revenue indicators:
Fundamental company analysis:RSLS (ReShape Lifesciences Inc)
To minimize risks during fundamental analysis, it is essential to correlate an asset's market value with expected sales expansion rates. In the case of ReShape Lifesciences (RSLS), an aggressive commercial strategy and a reliance on high-compensated medical sales representatives make the business's future P/S ratio a key indicator of investment viability. This metric divides current market capitalization by projected annual revenue, determining the cost of one dollar of future earnings.
Who ReShape Lifesciences competes with
Price-to-Projected Revenue Ratio Dexcom DXCM|PEN - Forward Price-to-Revenue Multiple|Novanta Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Haemonetics Company|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED) - Forward P/S Multiple|Pulse Biosciences Inc (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward Price-to-Revenue Multiple Picard Group PMI|Forward P/S Multiple SRDX (Surmodics, Inc.)|Forward P/S Multiple senseonics.com SENS|NPCE - Price-to-Projected Revenue Ratio|TCMD: Price-to-Projected Revenue Ratio|SNWV (SANUWAVE Health, Inc.) - Forward Price-to-Revenue Multiple|Outset Medical Corp - Forward Price to Sales|ELMD (SmartVest) - Forward P/S Multiple|Market Cap to Future Revenue Ratio lensar.com LNSR|Price-to-Projected Revenue Ratio AVITA Medical (RCEL)|profoundmedical.com (PROF) - Projected Price to Revenue|Baird Medical - Forward Price-to-Revenue Multiple|Forward P/S Multiple EDAP TMS SA EDAP|Bovie Medical - Forward P/S Multiple|Market Cap to Expected Sales Ratio IceCure Medical Ltd ICCM|pulmonx.com (LUNG) - Price-to-Projected Revenue Ratio|Future Price to Revenue TELA (TELA Bio)|Price-to-Projected Revenue Ratio CytoSorbents Corp|Forward Price-to-Revenue Multiple Sensus (SRTS)|Forward P/S Multiple ZYXI|ECOR - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Vicarious Surgical RBOT|IINN: Market Cap to Projected Revenue|ICU: Forward Price-to-Revenue Multiple|IRIDEX Corporation - Price to Expected Revenue Ratio|ibs.inc (INBS) - Price-to-Projected Revenue Ratio|Beyond Air - Forward Price to Sales|PFSA (Profusa) - Forward P/S Multiple|Market Cap to Future Revenue Ratio STRATA Skin SSKN|Price-to-Projected Revenue Ratio GlucoTrack (GCTK)|Market Cap to Expected Sales Ratio NanoVibronix Inc.|Forward P/S Multiple VERO (Venus Concept Inc.)|Forward Price to Sales NUWE|Aethlon Medical, Inc. - Forward P/S Multiple|ASXC - Forward P/S Multiple|Avinger, Inc (AVGR) - Price-to-Projected Revenue Ratio|Future Price to Revenue BSGM (Biosig Technologies)|CUTR (Cutera, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio knowlabs.co KNW|Forward Price-to-Revenue Multiple NARI (Inari Medical)|NVRO (Nevro Corp) - Forward Price to Sales|Price-to-Projected Revenue Ratio Silk Road Medical Inc. SILK
